News: ANP Antisense Therapeutics says ATL1102 for MS Phase IIb IND submitted to FDA for review, page-3

Great day for Anp...this fund took Iil to $1.88...they were their largest shareholder and Now ANP'S...

Following the settlement of the placement to Australian Ethical Investment, the Company proposes to undertake a pro-rata Entitlement Issue to shareholders at the same price to raise up to $2,000,000. Subject to approval to commence the trial being granted, Australian Ethical Investment has indicated its intention to take up its pro-rata entitlement and to acquire additional shortfall shares in ANP to increase its holding in the Company to 19.99%.